Healtcare ALK Positive Lung Cancer Treatment Market

ALK Positive Lung Cancer Treatment Market :Growth Factors,
Types and Application, Demand and Supply Chain Analysis,
Forecast To 2026
ALK positive lung cancer treatment is used for people suffering from lung cancer with Anaplastic
Lymphoma Kinase (ALK) mutation (the EML4-ALK fusion gene). This gene mutation is due to
gene rearrangement by fusion of two genes called as ALK and Echinoderm Microtubule-associated
protein Like 4 (EML4). The ALK gene fusion was first reported in 2007, in Non-small cell lung
cancer (NSCLC) patients.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2201
ALK Positive Lung Cancer Treatment Market Drivers
New drug approvals for treatment of ALK positive lung cancer is expected to drive growth of the
market. For instance, in August 2018, China National Drug Administration (CNDA) approved
Alecensa (alectinib) of F. Hoffmann-La Roche Ltd., for treatment of ALK-positive lung cancer.
Moreover, CNDA granted marketing authorization for Alecensa (alectinib), as monotherapy
treatment for patients with anaplastic lymphoma kinase (ALK)-positive and advanced non-small
cell lung cancer (NSCLC).